diagnost tool
broad io panel launch expand pharma
funnel keep us posit buy trim pt
htg deliv encourag updat launch proprietari
gene immuno-oncolog panel believ serv acceler htg grow
biopharma funnel biopharma interest build time htg de-risk
balanc sheet begin make opportunist hire sale forc
believ htg offer compel platform well-posit enabl pharma compani
develop novel therapi upon fda clearanc first panel transit clinic
compani opinion htg carv valuabl nich bustl precis
medicin industri reiter buy rate htg trim pt
result rev grew y/i driven strong growth ruo
profil servic biopharma custom came light htg
collabor revenu increas htg deliv
loss better expect loss htg reiter
revenu guid expect pharma deal funnel pois growth
launch i/o panel week htg launch edgeseq precis
immuno-oncolog panel view excit panel launch differenti
compani i/o panel seek quantifi express gene enabl
deep multiplex analysi checkpoint inhibit immun phenotyp inflamm
statu tumor biolog sub-typ tini amount sampl htg deliv
initi order custom work cancer immunolog immunotherapi
io panel research go raw sampl sequencing-readi librari littl
hour hour hands-on time htg develop analyt modul use
research look provid lab complet solut empow precis
medicin local level believ combin oncolog biomark panel
obp io offer increas demand biopharma partner
qiagen/bm collabor advanc target ngs-base companion diagnost
last week htg enter amend second statement work
master assay agreement potenti develop launch
ngs-base companion diagnost assay support one drug program
bristol-my squibb bm investigational-use-onli assay use
retrospect clinic trial htg hope assay use addit clinic
trial becom companion diagnost
sign master agreement oncologi htg oncologi inc announc
earli august agreement partner develop biomark associ
oncologi immuno-oncolog pipelin htg expect see revenu
collabor could mark upsid estim
edgeseq fda submiss htg indic pma submiss
lung fusion edgeseq alkplu assay use aid identif patient
elig treatment alk-target drug like crizotinib remain activ htg
intend proceed pma final time submiss
thu expect htg like earn fda approv
price close busi august
htg global diagnost compani decentr
rna molecular profil proprietari
platform edgeseq pursu multipl ngs-
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model inch rev given modest shortfal
versu expect compar consensu
compani reiter guidanc trim revenue estim
respect versu
consensu respect
reiter guid larg given htg visibl expand develop
biopharma precis diagnost partnership pdp program on-going revenu pull-
instrument consum well veri/o servic lab ruo profil
servic compani reiter revenu guid
sale forc ramp fortifi balanc sheet htg recent lot
breath room make import strateg invest busi posit
htg growth ahead htg remain track grow field-bas sale forc
sale rep end htg ad biopharma-focus rep
recent complet train
firali deal look beyond oncolog autoimmun diseas htg
announc deal france-bas biotech firali enabl firali develop
sequencing-bas theranost test predict rheumatoid arthriti patient respons
anti-tnf tumour necrosi factor alpha therapi humira view
compel applic outsid htg oncolog focu success
think bode well addit use autoimmun diseas time
increas breadth test applic beyond oncolog htg support frali
instrument reagent kit support firali commerci plan
merck kgaa htg announc decemb new master collabor agreement
merck kgaa complement prior master companion agreement merck
kgaa darmstadt germani includ statement work emd serono
biopharma busi merck kgaa htg plan develop manufactur custom
profil assay support biomark research indic within merck kgaa
develop pipelin assay expect kit use htg edgeseq
instrument acquir merck kgaa and/or contract research organ partner
addit panel launch expect htg announc plan launch
htg edgeseq mous microrna whole transcriptom assay htg edgeseq mous
messeng rna tumor respons assay htg launch two panel
respons rise custom demand earli translat studi use mous
model high volum htg expect panel yield higher volum sampl type
may catalyst drive instrument placement
balanc sheet htg materi strengthen balanc sheet end
rais gross net oversubscrib secondari offer htg
cash stand think good quarter oper run-way
buy unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin august et
date time product august et
pt use multipl revenu estim discount back year discount rate use
pro-forma share count million
price target appli multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth contribut accret capit
deploy would mark upsid adj ep estim
price target appli multipl adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep estim assum view
modest earn per share growth project believ potenti faster top-lin growth contribut
accret capit deploy would mark upsid adj ep estim
risk achiev target price valuat
risk htg includ competit product launch delay liquid risk commerci execut exist new product launch
futur work success pharmaceut compani expand presenc clinic regulatori risk
fda reimburs concern risk custom use htg panel macroeconom concern could impact custom
appetit purchase/us htg instruments/consum technolog chang could requir htg modifi platform
compet compani emerg space capit requir could requir htg rais addit capit futur
sever key product develop underway delay extend timelin could affect futur revenu earn
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
buy unchang target price august
diagnost tool
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
